DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.
Lymphoma, Non-Hodgkin
DRUG: DZD8586
Part A: Incidence of adverse events, 30 days after the last dose, assessed up to 2 years|Part B: Objective Response Rate assessed by investigators, assessed up to 2 years
Part A: Objective Response Rate assessed by investigators, assessed up to 2 years|Part A: Plasma and CSF concentration of DZD8586, through discontinuation of treatment up to 10 weeks|Part B: Duration of Response assessed by investigators, from date of first documented response until the date of documented progression, assessed up to 2 years|Part B: Incidence of adverse events, 30 days after the last dose, assessed up to 2 years|Part B: Plasma and CSF concentration of DZD8586, through discontinuation of treatment, assessed up to 2 years
This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.